Evidence map›Paper›PMID 31676703›Full record

ArticleThe Journal of rheumatology2020

Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus.

Sarah K Chen, Medha Barbhaiya, Daniel H Solomon, Hongshu Guan, Kazuki Yoshida, Candace H Feldman, Brendan M Everett, Karen H Costenbader

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Cardiac Involvement in Systemic Lupus Erythematosus.Reviews in cardiovascular medicine · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sarah K ChenFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA. schen30@bwh.harvard.edu.
Medha BarbhaiyaFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Daniel H SolomonFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Hongshu GuanFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Kazuki YoshidaFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Candace H FeldmanFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Brendan M EverettFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Karen H CostenbaderFrom the Division of Rheumatology, Immunology and Allergy, the Division of Pharmacoepidemiology and Pharmacoeconomics, and the Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Brigham and Women's Hospital · US

Funding

MECHANISMS OF ARTHRITIC &DERMATOLOGY DISORDERST32AR007530 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael B. Brenner, Ellen M Gravallese · 1986 to 2026
$10.4M
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial FactorsR01AR057327 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2009 to 2019
$6.2M
Cardiovascular Disease Epidemiology in Patients with LupusK24AR066109 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2014 to 2023
$1.7M
Avoidable Acute Care Use among Patients with LupusK23AR071500 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI FELDMAN, CANDACE HILLARY · 2017 to 2021
$945k
Inflammation Reduction to Prevent Atrial Fibrillation (CIRT-AF)R56HL134810 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI EVERETT, BRENDAN M · 2018 to 2018
$585k
Gout and Cardiovascular Comorbidities: Disentangling the Interplay with Advanced Methods to Address Measurement IssuesK23AR076453 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI YOSHIDA, KAZUKI · 2020 to 2022
$439k
NHLBI NIH HHS R56 HL134810NIAMS NIH HHS K23 AR071500NIAMS NIH HHS K23 AR076453NIAMS NIH HHS K24 AR066109NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR057327NIAMS NIH HHS T32 AR007530
6 · The paper itself

Abstract

objectiveSystemic lupus erythematosus (SLE) is a multisystem chronic inflammatory autoimmune disease with high prevalence of several risk factors for atrial fibrillation/flutter (AF). However, the incidence and risk of AF in SLE have not been well quantified.

methodsWe used the United States Medicaid Analytic eXtract from 2007 to 2010 to identify beneficiaries aged 18-65 years, with prevalent SLE, each matched by age and sex to 4 non-SLE general Medicaid recipients. We estimated the incidence rates (IR) per 1000 person-years (PY) for AF hospitalizations and used multivariable Cox regression to estimate the HR for AF hospitalization.

resultsWe identified 46,876 US Medicaid recipients with SLE, and 187,504 age- and sex-matched non-SLE controls (93% female; mean age 41.5 ± 12.2 yrs). Known AF risk factors such as hypertension (HTN), cardiovascular disease (CVD), and kidney disease were more prevalent in patients with SLE. During a mean followup of 1.9 ± 1.1 years for SLE, and 1.8 ± 1.1 years for controls, the IR per 1000 PY for AF was 1.4 (95% CI 1.1-1.6) among patients with SLE and 0.7 (95% CI 0.6-0.8) among non-SLE controls. In age- and sex-matched and race-adjusted Cox models, the HR for AF was 1.79 (95% CI 1.43-2.24); after adjustment for baseline HTN and CVD, the adjusted HR was reduced to 1.17 (95% CI 0.92-1.48).

conclusionSLE was associated with a doubled rate of hospitalization for AF compared to age- and sex-matched general Medicaid patients. In a race-adjusted model, the risk was 80% higher. However, the AF risk factors HTN and CVD were more prevalent among patients with SLE and accounted for the excess risk.

Indexed as

Atrial FibrillationLupus Erythematosus, SystemicAdultFemaleHospitalizationHumansIncidenceMaleMedicaidProportional Hazards ModelsRisk FactorsUnited StatesATRIAL FIBRILLATIONCARDIOVASCULAR DISEASEMEDICAIDSYSTEMIC LUPUS ERYTHEMATOSUS

Identifiers

PMID31676703
PMCPMC7192763
OpenAlexW2989549710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.